文献速递造血干细胞移植与细胞治疗白血病

接受第二次完全缓解期移植的AML患者:单倍体移植联合PTCy的无GVHD无复发生存优于无关供者移植——来自欧洲血液与骨髓移植学会急性白血病工作组的研究

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Am J Hematol · 2025-07-12

该研究基于欧洲血液与骨髓移植学会登记库2010至2022年间3878例接受首次异基因造血干细胞移植的第二次完全缓解期成人AML患者数据,比较单倍体供者联合移植后环磷酰胺(HAPLO PTCy)、同胞全合供者(MSD)和无关供者(MUD)移植结局。多因素分析显示,与MUD移植相比,HAPLO PTCy移植与更低的复发率、慢性GVHD及广泛型慢性GVHD发生率相关,并带来更优的无GVHD无复发生存(GRFS)(HR=0.81,95%CI 0.68-0.95;p=0.013)。

要点

  • 与MUD移植相比,HAPLO PTCy移植与更低的复发率(HR=0.64)、慢性GVHD(HR=0.64)及广泛型慢性GVHD(HR=0.47)相关。
  • HAPLO PTCy移植的GRFS优于MUD移植(HR=0.81,95%CI 0.68-0.95;p=0.013)。
  • 与MSD移植相比,HAPLO PTCy移植复发率更低(HR=0.65)但非复发死亡率更高(HR=1.77),GRFS无差异。

核心结论

  • 对于第二次完全缓解期AML患者,HAPLO PTCy移植与MUD移植相比与更低的复发率和慢性GVHD相关,并带来更优的GRFS。

研究设计与样本

  • 该研究为欧洲血液与骨髓移植学会登记库数据的分析,纳入2010至2022年间接受首次异基因造血干细胞移植的3878例第二次完全缓解期成人AML患者。
  • 研究采用单因素分析和Cox回归模型,分析803例HAPLO PTCy、1271例MSD和1804例MUD移植的结局。

主要发现

  • 欧洲白血病网(ELN2022)中危/高危细胞遗传学患者接受HAPLO PTCy移植的比例(80.7%)高于MUD(79.6%)或MSD(70.2%)。
  • 多因素分析中,与MSD移植相比,HAPLO PTCy移植与更低的复发率相关(HR=0.65,95%CI 0.51-0.82;p<0.001),但非复发死亡率更高(HR=1.77,95%CI 1.34-2.34;p<0.001)。
  • HAPLO PTCy与MSD移植相比,无白血病生存和GRFS无差异。
  • 与MUD移植相比,HAPLO PTCy移植与更低的复发率(HR=0.64,95%CI 0.48-0.82;p<0.001)、慢性GVHD(HR=0.64,95%CI 0.51-0.81;p<0.001)及广泛型慢性GVHD(HR=0.47,95%CI 0.34-0.66;p<0.001)相关。
  • HAPLO PTCy移植的GRFS优于MUD移植(HR=0.81,95%CI 0.68-0.95;p=0.013)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor preference for acute myeloid leukemia (AML) patients transplanted in second complete remission (CR2) remains unclear, and hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) from a haploidentical donor (HAPLO) merits attention. Data of 3878 adult AML patients receiving a first allo-HCT in CR2 from the European Society of Blood and Marrow Transplantation registry between 2010 and 2022 were analyzed. Univariate analyses and Cox regression models were used. Results of HCTs from 803 HAPLO PTCy, 1271 matched sibling donor (MSD), and 1804 matched unrelated donor (MUD) were analyzed. A higher proportion (80.7%) of patients with European LeukemiaNet (ELN2022) intermediate-/adverse-risk cytogenetics received an allo-HCT from HAPLO PTCy than from either MUD (79.6%) or MSD (70.2%). On multivariate analysis, HAPLO PTCy grafts (hazard ratio [HR] = 0.65, 95% confidence interval [CI] 0.51-0.82; p < 0.001) were associated with a lower relapse incidence (RI) compared with MSD HCTs, although non-relapse mortality was higher (HR = 1.77, 95% CI 1.34-2.34; p < 0.001). No difference was observed with respect to leukemia-free survival and graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) for HAPLO PTCy compared to MSD grafts. Notably, HAPLO PTCy HCT was associated with significantly lower RI (HR = 0.64, 95% CI 0.48-0.82; p < 0.001), chronic GVHD (cGVHD) (HR = 0.64, 95% CI 0.51-0.81; p < 0.001) and extensive cGVHD (HR = 0.47, 95% CI 0.34-0.66; p < 0.001) incidences compared to MUD HCTs. Collectively, HAPLO PTCy HCT was associated with superior GRFS (HR = 0.81, 95% CI 0.68-0.95; p = 0.013) than MUD HCT. For AML patients in CR2, HAPLO PTCy HCT is associated with lower RI and cGVHD, leading to superior GRFS compared with MUD HCTs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ye Y, Labopin M, Yakoub-Agha I, et al. Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2025. PMID: 40650544. doi:10.1002/ajh.70008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。